Vaccine-induced immune thrombotic thrombocytopenia: current evidence, potential mechanisms, clinical implications, and future directions. Issue 2 (2nd August 2021)

• Record Type: Journal Article
• Authors: Marchandot, Benjamin; Curtiaud, Anais; Trimaille, Antonin; Sattler, Laurent; Grunebaum, Lelia; Morel, Olivier
• Editors: Li, Nailin
• Is Part Of: European Heart Journal Open. Volume 1:Issue 2(2021)
• Publication Date: 2021-08-02
• Subjects: COVID-19 -- Vaccine -- Thrombosis -- Venous thromboembolism -- Cerebral sinus venous thrombosis -- Thrombocytopenia vaccine-induced immune thrombotic thrombocytopenia -- PF4; 616
• DOI: 10.1093/ehjopen/oeab014
• Languages: English
• ISSNs: 2752-4191

Abstract

Abstract: Vaccine-induced immune thrombotic thrombocytopenia (VITT) (also termed thrombosis with thrombocytopenia syndrome or vaccine-induced thrombotic thrombocytopenia or vaccine-induced immune thrombocytopenia) is characterized by (i) venous or arterial thrombosis; (ii) mild-to-severe thrombocytopenia; (iii) positive antiplatelet factor 4 (PF4)–polyanion antibodies or anti-PF4–heparin antibodies detected by the HIT (heparin-induced thrombocytopenia) ELISA; (iv) occurring 5–30 days after ChAdOx1 nCoV-19 (AstraZeneca) or Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination. VITT's incidence is 1 per 100 000 vaccinated people irrespective of age and up to 1 in 50 000 for people <50 years of age with the AstraZeneca COVID-19 vaccine. The exact mechanism by which adenovirus-vectored COVID-19 vaccines trigger this syndrome is still unclear, as for the increased risk for acute cerebral sinus venous thrombosis and splanchnic vein thrombosis as compared to other locations of venous thrombotic events. VITT is associated with the detection of anti-PF4 antibodies, unrelated to previous use of heparin therapy. PF4 antibodies are thought to activate platelets via the platelet FcγRIIA receptors leading to further platelet activation that causes thrombosis and thrombocytopenia. Graphical Abstract: